Tirzepatide for Weight Loss in Long Island, New York
Dual GLP-1 & GIP-based treatment — physician-guided tirzepatide care
Physician-guided tirzepatide care for patients who want a stronger weight loss option with close medical oversight, thoughtful dose titration, and ongoing follow-up from the StackMD team serving Nassau and Suffolk County. Prefer a single-hormone approach? We also offer semaglutide weight loss starting at $149/month.
- Physician-guided care
- Long Island, NY based
- Telehealth follow-up available
In-office care with telehealth follow-up available · Nassau & Suffolk County
- Physician-prescribed & monitored
- Starting at $199/month
- Zepbound & Mounjaro options
- Telehealth & in-office visits
- Insurance assistance provided
22.5%
avg. body weight lost on 15 mg dose (SURMOUNT-1, 72 weeks)
~47%
greater weight loss than semaglutide in head-to-head trial (NEJM, 2025)
2-in-1
dual GLP-1 & GIP receptor agonist — first-of-its-kind mechanism
What Is Tirzepatide
A Higher-Potency Option for Medical Weight Loss
Tirzepatide is a once-weekly injectable medication that acts as both a GLP-1 receptor agonist and a GIP (glucose-dependent insulinotropic polypeptide) receptor agonist — making it the first dual-hormone weight loss therapy of its kind. This is what separates tirzepatide from single-pathway options like semaglutide weight loss treatment.
By targeting two separate metabolic pathways simultaneously, tirzepatide may deliver weight loss outcomes that exceed those of GLP-1-only medications. It is FDA-approved for chronic weight management under the brand name Zepbound, and for type 2 diabetes under Mounjaro — both manufactured by Eli Lilly.
In the landmark SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in May 2025, tirzepatide produced nearly 50% greater weight loss than semaglutide in adults with obesity over 72 weeks. StackMD offers tirzepatide treatment with physician oversight at our Long Island practice.
How Tirzepatide Works
Dual Receptor Activation
Activates both GLP-1 and GIP receptors — two independent pathways that regulate hunger, satiety, insulin secretion, and energy storage.
Superior Appetite Suppression
The combination of GLP-1 and GIP action is designed to reduce appetite more significantly than GLP-1 alone.
Enhanced Insulin Sensitivity
GIP agonism may strengthen insulin release and improve insulin sensitivity — important for metabolic dysfunction and prediabetes.
Slowed Gastric Emptying
Prolongs fullness between meals by slowing the movement of food through the digestive tract.
Clinical Evidence
Head-to-Head: Tirzepatide vs. Semaglutide
In the SURMOUNT-5 trial published in the New England Journal of Medicine (May 2025), adults with obesity but without type 2 diabetes were randomized to the maximum tolerated dose of tirzepatide or semaglutide for 72 weeks. The results consistently favored tirzepatide.
Tirzepatide produced an average weight loss of 20.2% versus 13.7% with semaglutide — a difference of nearly 50%. Tirzepatide was also superior across every secondary endpoint including waist circumference reduction and achieving 10%, 15%, 20%, and 25% weight loss thresholds. Individual results may vary.
20.2%
avg. weight loss with tirzepatide at 72 weeks
13.7%
avg. weight loss with semaglutide at 72 weeks
~52 lbs
avg. lost at the 15 mg dose in SURMOUNT-1
47%
greater relative weight loss versus semaglutide in the head-to-head trial
72
weeks of treatment and follow-up in the published comparison study
4/4
major weight-loss thresholds favored tirzepatide, including 10%, 15%, 20%, and 25%
Your Program at StackMD
How the Program Works
From your first consultation to ongoing dose optimization, every step is guided by your StackMD physician.
Physician Consultation
Your StackMD physician reviews your complete medical history, weight-related conditions, prior treatment history, and goals — via telehealth or in-office in Long Island, Nassau or Suffolk County.
Advanced Lab Testing
Comprehensive metabolic labs including hormones, blood sugar, inflammation markers, and lipid panel. Labs help determine if tirzepatide or semaglutide is the better clinical fit for you.
Prescription & Training
You receive your individualized tirzepatide prescription with detailed injection instructions, dosing schedule starting at 2.5 mg, and nutritional guidance.
Dynamic Monitoring
Regular physician follow-ups allow dose adjustment every 4 weeks based on tolerance and response — up to the maximum 15 mg therapeutic dose.
Your program. Your pace. Real physician oversight.
Most patients are seen within a few days of reaching out. Every step — from labs to dosing — is guided by your StackMD physician.
Program Pricing
Tirzepatide Options at StackMD
Pricing reflects the medication, program structure, and clinical services included. Contact our office for current pricing and coverage assistance. Looking for a more affordable entry point? Semaglutide weight loss starts at $119/month.
$199/mo
starting price per month
Physician-guided compounded tirzepatide with flexible dosing and titration when clinically appropriate. Pricing depends on dose, formulation, and program structure.
$349/mo
per month without insurance
Eli Lilly’s LillyDirect program may offer cash-pay vial access at $349–$499 depending on dose for patients without insurance coverage.
$25/mo
based off copay and insurance coverage
Branded Zepbound through insurance. Coverage varies by plan. Please contact your insurance first.
Pricing is based on clinical evaluation and services selected. Contact our office for current pricing and coverage assistance.
Have pricing questions? We'll walk you through your options.
Tirzepatide programs are available at multiple price points. We also assist with insurance verification and prior authorization for branded Zepbound.
Candidacy
Who May Be a Good Fit for Tirzepatide?
Every step of your semaglutide program is guided by your StackMD physician — in Nassau County, Suffolk County, or anywhere on Long Island, NY.
BMI of 30 or higher (obesity)
BMI of 27 or higher with at least one weight-related complication (high blood pressure, type 2 diabetes, obstructive sleep apnea)
Patients who have tried GLP-1 therapy and may benefit from stronger metabolic support
Adults seeking one of the highest-efficacy injectable options currently available for weight management
Please note: Tirzepatide is not appropriate for individuals with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. It cannot currently be legally compounded as it is no longer on the FDA drug shortage list. Candidacy is determined by your physician following a full clinical evaluation.
Frequently Asked Questions
Questions Patients Ask About Tirzepatide
How much weight can I lose on tirzepatide?
In clinical trials, patients on the 15 mg dose lost an average of 20–22.5% of their body weight over 72 weeks. In the SURMOUNT-5 head-to-head trial against semaglutide (NEJM, 2025), tirzepatide may produce nearly 50% greater weight loss on average. Individual results may vary based on dose, duration, lifestyle, and metabolic factors.
How is tirzepatide different from semaglutide?
Is tirzepatide available in Long Island — Nassau County and Suffolk County?
Do I need labs before starting tirzepatide?
What is the difference between Zepbound and Mounjaro?
Can tirzepatide be used to treat sleep apnea?
How long does it take to see results?
Is tirzepatide covered by insurance?
Patient Experiences
Real patients. Real results.
“I’d tried everything before this. Within three months on tirzepatide through StackMD, I was down 28 pounds. The physician check-ins made all the difference — I never felt like I was figuring it out alone.”
Jennifer M. — Nassau County
“What I appreciated most was the lab review before they prescribed anything. It felt like actual medicine, not just handing me a medication. My doctor reviewed everything and explained exactly why tirzepatide was the right fit.”
David R. — Suffolk County
“My sleep apnea was the main reason I started, but the weight loss has been incredible too. Down 41 pounds in seven months. StackMD made the whole process easy — telehealth appointments, quick dose adjustments, no hassle.”
Marcus T. — Long Island
Explore More Options
Other Weight Loss Programs at StackMD
Injectable · GLP-1
Semaglutide (Wegovy)
Including the new high-dose Wegovy HD at 7.2 mg. Semaglutide weight loss programs starting at $149/month with physician oversight in Long Island.
Oral · No Injections
Oral GLP-1 (Wegovy Pill)
FDA-approved December 2025. The first weight loss pill with proven GLP-1 efficacy. No needles, once daily.
All Options
Medical Weight Loss Program
View our full weight loss program overview and compare all available medications and protocols.
Ready to Begin Your Tirzepatide Program?
StackMD serves patients across Long Island, Nassau County, Suffolk County, and surrounding New York areas. In-office and telehealth appointments available.